Biotechnology is viewed as an industry that combines scientific innovation, entrepreneurial management and experienced investment to drive innovation, primarily in biomedicine. This paper examines the third of these assumed preconditions. We find that the majority of investors in biotechnology companies over the last decade by number or by value have not been experienced, and that the majority of investors in biotechnology companies have invested in less than three such companies in the decade, suggesting that they have very limited experience of biotechnology. 13% of investment syndicates contain no investors who have made more than three biotechnology investments. Investor inexperience is disproportionately high in Seed and Series A rounds, but has little correlation with amount invested. Investor inexperience is found in all categories of investors and all territories, although US investors tend to have greater experience than those outside North America. The banking crisis of 2008-11 has not materially changed this. We suggest that the conventional image of biotechnology investment as the careful selection and nurturing of young companies by experienced investors is incomplete. This has implications for candidate investor selection by entrepreneurs, and for government support of biotechnology by supporting investors or investment mechanisms.Â
Lee, D.P. and M.D. Dibner, The rise of venture capital and biotechnology in the US and Europe. Nature Biotechnology, 2005. 23(6): p. 672 - 676. http://www.nature.com/nbt/journal/v23/n6/abs/nbt0605-672.html
Bradford, T.C., Evolving symbiosis - venture capital and biotechnology. Nature Biotechnology, 2003. 21(9): p. 983 - 984. http://www.nature.com/nbt/journal/v21/n9/full/nbt0903-983.html
Browning, J., The incredible shrinking venture capital. Nature 2009. 460: p. 459. http://www.nature.com/nature/journal/v460/n7254/full/460459a.html
Huggett, B., Biotech's wellspring: a survey of the health of the private sector. Nat Biotech, 2012. 30(5): p. 395-400. http://www.nature.com/nbt/journal/v30/n5/full/nbt.2209.html
Festel, G. and C. Rammer, Importance of venture capital investors for the industrial biotechnology industry. Journal of Commercial Biotechnology, 2015. 21(2): p. 31 - 42. http://commercialbiotechnology.com/index.php/jcb/article/view/685
PriceWaterHouseCoopers LLC, Biotech funding surges. Q4 2014 Life Sciences Report. 2015, PriceWaterHouse Coopers LLC. p. http://www.pwcmoneytree.com/Reports/FullArchive/Life%20Sciences_2014-4.pdf
Carroll, J., Dominant VC NEA gathers $3B megafund, preps for a wave of biotech rounds, in Fierce Biotech. 2015, Questex Media Group LLC: Newton, MA, USA. p. http://www.fiercebiotech.com/story/dominant-vc-nea-gathers-3b-preps-another-wave-biotech-rounds/2015-04-15.
Huggett, B., Biotech's wellspring[mdash]a survey of the health of the private sector in 2014. Nat Biotech, 2015. 33(5): p. 470-477. http://www.nature.com/nbt/journal/v33/n5/full/nbt.3218.html
Philippidis, A., Cost, Competitive Pressures Could Push Biotechs to More M&A Deals, in Genetic Engineering News. 2015, Mary Anne Liebert Inc: New York, NY, USA. p. http://www.genengnews.com/gen-news-highlights/ey-cost-competitive-pressures-could-push-biotechs-to-more-m/81251385/.
Bains, W., S. Wooder, and D.R.M. Guzman, Funding biotech start-ups in a post-VC world. Journal of Commercial Biotechnology, 2014. 20(1): p. 10 - 27. http://logos-press.com/journals/index.php/jcb/article/view/628
Ford, D. and B. Nelsen, The view beyond venture capital. Nat Biotech, 2014. 32(1): p. 15-23. http://www.nature.com/nbt/journal/v32/n1/full/nbt.2780.html
Ernst & Young LLP, Globalizing venture capital: Global venture capital insights and trends report 2012, Ernst & Young LLP: London, UK.
Huggett, B. and R. LÃ¤hteenmaki, Public biotech 2011 - by the numbers. Nature Biotechnology, 2012. 30: p. 751 - 757. http://www.nature.com/nbt/journal/v30/n8/full/nbt.2320.html
Cambridge Associates LLC, Cambridge Associates LLC U. S. Venture Capital Index and selected benchmark statistics. 2011, National Venture Capital Association: Boston, MA. http://www.endowmentwm.com/wp-content/uploads/2013/05/2012-Q4-NVCA-Benchmark-Book.pdf
Booth, B.I. and B. Salehizadeh, In defence of life science venture investing. Nature Biotechnology, 2011. 29(7): p. 579 - 583. http://www.nature.com/nbt/journal/v29/n7/abs/nbt.1908.html
Bains, W., Venture Capital and the European Biotechnology Industry. 2008, Basingstoke, UK: Palgrave Macmillan. http://www.williambains.co.uk/vcbio/
Mulcahy, D., B. Weeks, and H.S. Bradley, We have met the enemy ... and he is us. Lessons from twenty years of the Kauffman Foundation's investments in Venture Capital Funds and the triumph of hope over experience. 2012, Ewing Marion Kauffmann Foundation: Kansas City, MO. http://www.kauffman.org/~/media/kauffman_org/research%20reports%20and%20covers/2012/05/we_have_met_the_enemy_and_he_is_us.pdf
Sahlman, W.A., The structure and governance of venture-capital organizations., in Venture Capital, M. Wright and K. Robbie, Editors. 1997, Dartmouth: Aldershot, UK. p. 3 - 51. [No web site]
Gompers, P. and J. Lerner, The venture capital revolution. Journal of Economic Perspectives, 2001. 15(2): p. 145 - 168. http://www.jstor.org/stable/2696596
Gompers, P.A. and J. Lerner, The Venture Capital Cycle: 2nd edition. 2004, Cambridge, MA: MIT Press. [No web site]
Gorman, M. and W.A. Sahlman, What do venture capitalists do? Journal of Business Venturing, 1989. 4: p. 231 - 248. http://www.sciencedirect.com/science/article/pii/0883902689900141
Sapienza, H.J., When do venture capitalists add value? Journal of Business Venturing, 1992. 7(1): p. 9-27. http://www.sciencedirect.com/science/article/pii/088390269290032M
MacMillan, I.C., D.M. Kulow, and R. Khoylian, Venture capitalists' involvement in their investments: extent and performance, in Venture Capital, M. Wright and K. Robbie, Editors. 1997, Dartmouth: Aldershot, UK. p. 246 - 265. http://www.sciencedirect.com/science/article/pii/0883902689900323
Anon, Biotech hamstrung by investment strategies. Chemistry and Industry, 2004. 2004(1): p. 5. [No web site]
Bains, W., What you give is what you get: investment in European biotechnology. Journal of Commercial Biotechnology, 2006. 12(4): p. 274 - 283. http://logos-press.com/journals/index.php/jcb/article/view/177
Riquelmo, H. and J. Watson, Do venture capitalists' implicit theories on new business success/failure have empirical validity? International Small Business Journal, 2002. 20(4): p. 395 - 420. http://isb.sagepub.com/content/20/4/395.short
Dimov, D.P. and D.A. Shepherd, Human capital theory and venture capital firms: exploring 'home runs' and 'strike outs'. Journal of Business Venturing, 2005. 20(1): p. 1 - 21. http://www.sciencedirect.com/science/article/pii/S0883902604000035
Busenitz, L.W., J.O. Fiet, and D.D. Moesel, Reconsidering the venture capitalists' â€œvalue addedâ€ proposition: An interorganizational learning perspective. Journal of Business Venturing, 2004. 19(6): p. 787-807. http://www.sciencedirect.com/science/article/pii/S0883902603001058
Cumming, D., G. Fleming, and J.-A. Suchard, Venture capitalist value-added activities, fundraising and drawdowns. Journal of Banking and Finance, 2005. 29(2): p. 295 - 331. http://www.sciencedirect.com/science/article/pii/S0378426604000378
Lutz, E., et al., Importance of spatial proximity between venture capital investors and investees in Germany. Journal of Business Research, 2013. 66(11): p. 2346-2354. http://www.sciencedirect.com/science/article/pii/S0148296312001245
Clarysse, B., A. Bobelyn, and I.d.P. Aguirre, Learning from own and othersâ€™ previous experience: the contribution of the venture capital firm to the likelihood of a portfolio companyâ€™s trade sale. Small Business Economics, 2013. 40(3): p. 575 - 590. http://link.springer.com/article/10.1007/s11187-011-9381-0
Taylor, J., Implications of Financing Your Biotechnology Start-up, in Nature / TradeSecrets. 2011, Nature Publishing Group: London, UK. [No web site]
Springham, D.G., V. Moses, and R.E. Cape, Biotechnology - The Science and the Business. 1999, Washington, DC, USA: CRC Press. https://www.crcpress.com/Biotechnology---The-Science-and-the-Business/Springham-Moses-Cape/p/book/9789057024078
Kolchinsky, P., The entrepreneur's guide to a biotech start-up. 2004, Boston, MA, USA: Evelexa. http://uccai.ctsi.ucla.edu/file-storage/view/docs/EGBS4_Kolchinsky.pdf
De Rubertis, F., R. Fleck, and W. Lanthaler, Six secrets to successâ€”how to build a sustainable biotech business. Nat Biotech, 2009. 27(7). http://www.nature.com/nbt/journal/v27/n7/abs/bioe.2009.5.html
Brown, J., Venture capital and firm performance over the long-run: Evidence from high-tech IPOs in the United States. Journal of Entrepreneurial Finance, 2005. 10(3): p. 1-33. [no web site]
Davila, A., G. Foster, and M. Gupta, Venture capital financing and the growth of startup firms. Journal of Business Venturing, 2003. 18(6): p. 689-708. http://www.sciencedirect.com/science/article/pii/S0883902602001271
Croce, A., J. MartÃ, and S. Murtinu, The impact of venture capital on the productivity growth of European entrepreneurial firms: â€˜Screeningâ€™ or â€˜value addedâ€™ effect? Journal of Business Venturing, 2013. 28(4): p. 489-510. http://www.sciencedirect.com/science/article/pii/S0883902612000705
Baum, J.A.C. and B.S. Silverman, Picking winners or building them? Alliance, intellectual, and human capital as selection criteria in venture financing and performance of biotechnology startups. Journal of Business Venturing, 2004. 19(3): p. 411-436. http://www.sciencedirect.com/science/article/pii/S0883902603000387
Ernst & Young LLP, Beyond Borders 2013. . 2013, Ernst and Young LLP: London, UK. http://www.ey.com/Publication/vwLUAssets/Beyond_borders/$FILE/Beyond_borders.pdf
Gorman, M. and W.A. Sahlman, What do venture capitalists do? Journal of Business Venturing, 1989. 4(4): p. 231-248. http://www.sciencedirect.com/science/article/pii/0883902689900141
Janney, J.J. and T.B. Folta, Moderating effects of investor experience on the signaling value of private equity placements. Journal of Business Venturing, 2006. 21(1): p. 27-44. http://www.sciencedirect.com/science/article/pii/S0883902605000443
Zider, B., How venture capital works. Harvard Business Review, 1998. 1998(December). [No Web Site]
Lerner, J., The Syndication of Venture Capital Investments. Financial Management, 1994. 23(3): p. 16-27. http://www.jstor.org/stable/3665618
Busenitz, L.W., J.O. Fiet, and D.D. Moesel, Signalling in venture capitalist-new venture team funding decisions: does it indicate long-term venture outcomes? International Small Business Journal, 2005. 29(1): p. 1 - 12. http://onlinelibrary.wiley.com/doi/10.1111/j.1540-6520.2005.00066.x/full
Hsu, D.H., What do entrepreneurs pay for venture capital affiliation? Journal of Finance, 2004. 59(4): 1805 - 1844. http://onlinelibrary.wiley.com/doi/10.1111/j.1540-6261.2004.00680.x/full.
Booth, B.L., This time may be different. Nat Biotech, 2016. 34(1): p. 25-30. http://www.nature.com/nbt/journal/v34/n1/abs/nbt.3452.html
Crawford, M., Biotech Market Changing Rapidly. A shakeout looms as investment wanes and cash reserves dip; delays, competition affect all but the fittest biotech ventures. Science, 1986. 231(4733): p. 12-14. http://science.sciencemag.org/content/231/4733/12
Ernst, D. and D. Mackie, Fighting the Financing Frenzy: What Next for Biotechnology Companies? Nat Biotech, 1988. 6(5): p. 495-501. http://www.nature.com/nbt/journal/v6/n5/full/nbt0588-495.html
Howell, M., M. Trull, and M.D. Dibner, The rise of European venture capital for biotechnology. Nat Biotech, 2003. 21(11): p. 1287-1291. http://www.nature.com/nbt/journal/v21/n11/full/nbt1103-1287.html
Martino, P., The micro VC shakeout, TechCrunch, Editor. 2015, TechCrunch. http://techcrunch.com/2015/04/26/the-microvc-shakeout/
Lee, D.P. and M.D. Dibner, The rise of venture capital and biotechnology in the US and Europe. Nat Biotech, 2005. 23(6): p. 672-676. http://www.nature.com/nbt/journal/v23/n6/full/nbt0605-672.html
Fleming, J.J., The Decline Of Venture Capital Investment In Early-Stage Life Sciences Poses A Challenge To Continued Innovation. Health Affairs, 2015. 34(2): p. 271-276. http://content.healthaffairs.org/content/34/2/271.short
Dembosky, A., US venture capital investment declines, in Financial Times (London). 2012, FT: London. [no cuurent Web Page]
Lash, A. and T. Salemi, Venture capital survey paints bleak portrait, in The Pink Sheet. 2012, Elsevier: Bridgewater, NJ. p. 17 - 19. https://www.pharmamedtechbi.com/publications/the-pink-sheet/74/40/venture-capital-survey-paints-bleak-portrait
Tam, P.-W., Venture-Capital Firms Caught in a Shakeout, in Wall Street Journal. 2010, Wall Street Journal: New York, NY, USA. http://www.wsj.com/articles/SB10001424052748703915204575104221092909884http://www.wsj.com/articles/SB10001424052748703915204575104221092909884.
Waters, R., Investment fears in venture capital shake-out, in Financial Times. 2009, FT: London, UK. p. http://www.ft.com/cms/s/2/c78a2fc0-da8b-11dd-8c28-000077b07658.html#axzz41e9iZrlG.
Nanda, R. and M. Rhodes-Kropf, Investment cycles and startup innovation. Journal of Financial Economics, 2013. 110(2): p. 403-418. http://www.sciencedirect.com/science/article/pii/S0304405X13001967
Groysberg, B., Chasing Stars: The Myth of Talent and the Portability of Performance 2011, Princeton, NJ: Princeton University Press. http://press.princeton.edu/titles/9128.html
Thakor, A.V., Comment on Trester. Journal of Banking and Finance, 1998. 22(6 - 8): p. 700 - 701. [No Web Page]
Birch, D., The job creation process. 1979, M.I.T. programme on neighborhood and regional change: Cambridge, MA. [No Web Page]
Lambert, R., Lambert Review of Business-University Collaboration: final report. 2003, HMSO: London, UK. http://eua.be/eua/jsp/en/upload/lambert_review_final_450.1151581102387.pdf
UKTI, Bioscience UK. 2008, UK Trade and Investment: London. [No Web Page]
Unless specified by prior arrangement, the author agrees to the following terms and assurances:
- For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
- I/we further give to the following assurances
- I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
- I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
- To the best of my/our knowledge, all the facts in the contribution are true and accurate;
- The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
- Nothing in the contribution is obscene or libellous;
- Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
- I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).